Remyelination in MS – what progress has been made?
The review in brief
A recent review has outlined the progress made so far in understanding the biology of remyelination, what goes wrong in MS, some of the research problems that need to be tackled and the prospect for treatments in the not-too-distant future.
Considerable progress has been made in understanding the biology of remyelination. This has identified potential treatments, such as clemastine, opicinumab and bexarotene which are being tested in clinical trials.
The review shows that a good deal of progress has already been made, although there is still much to be done. The authors finish by identifying questions that further research needs to address in order to build on this work.
The review in more detail
Background
Treatments for MS have come a long way over the last two decades. There is a growing list of drugs for relapsing remitting MS, with Ocrevus now approved for primary progressive MS and siponimod going through assessment by the European Medicines Agency. All of these drugs act by reducing the immune attack which causes inflammation and damage to the myelin coating around nerve cells in the brain and spinal cord.
Although these drugs can reduce damage to myelin, they can’t stop it completely or repair damage that has happened. Your body can replace damaged myelin but this process is impaired in MS. Treatments which promote remyelination would offer the potential to delay, prevent or reverse disability and a great deal of research is exploring this. A recent review has outlined the progress made so far in understanding the biology of remyelination, what goes wrong in MS, some of the research problems that need to be tackled and the prospect for treatments in the not-too-distant future.
How does remyelination work and what goes wrong?
An important first step in developing treatments is understanding how remyelination works in health. The picture that is emerging is a complex interaction between different cell types and chemicals produced by the cells.
In the brain and spinal cord, cells called oligodendrocytes produce myelin which they wrap around nerve axons, like a Swiss roll. An important focus of research has been understanding the different steps that immature oligodendrocytes (oligodendrocyte progenitor cells, OPCs) go through before they can produce new myelin.
Large numbers of OPCs are seen in demyelinated MS lesions, so one theory is that remyelination fails because these immature cells are unable to mature into oligodendrocytes capable of making myelin. However, recent research using brain tissue from people with MS suggests that remyelination is mostly carried out by pre-existing and not newly matured oligodendrocytes. Another recent study found several types of mature oligodendrocytes and differences in the ratios of these subtypes in people with MS compared to healthy people. These two studies raise questions about how well the models used to research remyelination represent the process in humans.
Electrical activity in nerves has been found to stimulate remyelination, suggesting that intact nerve axons are necessary for successful repair. Perhaps related to this is the recent finding that access to a running wheel in a lab model of demyelination improved maturation of oligodendrocytes, the rate of remyelination and the proportion of remyelinated nerve axons. Combining physical activity with clemastine (see below) further enhanced remyelination.
The debris left over from damage to myelin has been shown to inhibit remyelination so the clearance of debris by macrophages and the role of other cell types found in brain tissue, such as astrocytes and microglia, is another area of research.
Remyelination reduces with age and disease duration. This may have important consequences for designing clinical trials and deciding when in the course of MS remyelination treatments would be most effective. It may be possible to counteract some of the consequences of ageing – a recent study reported that in a lab model of demyelination, alternate day fasting or treatment with metformin, a type 2 diabetes drug which can mimic the effects of calorie restriction, can recalibrate ageing OPCs to remyelinate axons.
Remyelination clinical trials
The good news is that research is beginning to identify potential treatments which are being tested in clinical trials. However, one of the biggest difficulties for clinical trials is demonstrating that a drug is having an effect by promoting remyelination. Advanced MRI techniques and PET (positron emission tomography) scans are being developed. Another approach is to use evoked potentials to measure the speed of electrical messages along sensory nerves to the brain.
A protein called Lingo-1 prevents OPCs developing into functioning oligodendrocytes. Opicinumab blocks the action of Lingo-1, allowing OPCs to mature. In a phase II study of people diagnosed with optic neuritis, opicinumab improved transmission of nerve impulses in the optic nerve, suggesting that remyelination had occurred. A second phase II study used a combination of Avonex (interferon beta 1a) and opicinumab but found neither an improvement in disability nor a slowdown in progression. These results were disappointing, but further analysis suggested some improvement in a subset of the participants. It is now being tested in a further study as an add-on to disease modifying drugs in relapsing MS.
Another route to discovering candidates is through testing large numbers of molecules in laboratory models of OPC development. This approach identified clemastine, a drug normally used to treat allergies. In a phase II clinical trial in 50 participants with relapsing MS and evidence of long term damage to the optic nerve, clemastine treatment resulted in a small improvement in the speed at which nerve impulses passed along the optic nerve. There was a slight improvement in vision, but too small for this to be conclusive. The researchers were unable to show the repair on MRI scans and other measures of myelin. Clemastine is now being tested in a second phase II trial in people with acute optic neuritis.
The review lists further clinical trials of potential remyelinating treatments, including bexarotene, biotin and cell-based therapies, which have been completed or are underway.
What does it mean?
This review shows that a good deal of progress has already been made, although there is still much to be done. The authors finish by identifying questions that need to be answered in order to build on this work:
- How well does remyelination in animals match the process in people with MS?
- What is the best way to measure remyelination in clinical studies?
- When would be the best time to start a remyelinating treatment?
- Which is the most appropriate group of people with MS for testing remyelinating treatments?
Cunniffe N, Coles A.
Promoting remyelination in multiple sclerosis.
Journal of Neurology 2019 Jun 12. [Epub ahead of print]
Read the full article
The role of myelin
Myelin is the layer of fatty protein wrapped around the axons of nerve cells. It acts as insulation, speeding up the transmission of electrical impulses along nerve axons. Loss of myelin slows down or blocks nerve impulses and, once exposed, nerve axons can be damaged and lost.
The myelin sheath has short gaps about one micrometre apart known as Nodes of Ranvier. Nerve messages leap along the axon from node to node. The thickness of the myelin sheath and the size of the gap between nodes determine the speed of messages, which can be as fast as 120 metres/second (268mph).
Nerve cells are surrounded by support cells called glial cells. These include oligodendrocytes which produce myelin.
Find out more about nerve cells (neurons), myelin and oligodendrocytes.
Browse more from the latest research
Assessment tools
D'Souza M, Heikkilä A, Lorscheider J, Haller V, Kravalis K, Gysin S, Fuertes NAC, Fricker E, Lam E, Higgins P, Tomic D, Papadopoulou A, Kappos L.
Electronic Neurostatus-EDSS increases the quality of expanded disability status scale assessments: Experience from two phase 3 clinical trials.
Mult Scler. 2019 May 7:1352458519845108. doi: 10.1177/1352458519845108. [Epub ahead of print]
Summary(link is external)
Causes of MS
Pantavou KG, Bagos PG.
Season of birth and multiple sclerosis: a systematic review and multivariate meta-analysis.
J Neurol. 2019 May 4. doi: 10.1007/s00415-019-09346-5. [Epub ahead of print] Review.
Summary(link is external)
Childhood MS
Brenton JN, Koshiya H, Woolbright E, Goldman MD.
The Multiple Sclerosis Functional Composite and Symbol Digit Modalities Test as outcome measures in pediatric multiple sclerosis.
Mult Scler J Exp Transl Clin. 2019 Apr 29;5(2):2055217319846141. doi: 10.1177/2055217319846141. eCollection 2019 Apr-Jun.
Summary(link is external)
Read the full text of this paper (link is external)
Sikes EM, Richardson EV, Motl RW.
A qualitative study of exercise and physical activity in adolescents with pediatric-onset multiple sclerosis.
Int J MS Care. 2019 Mar-Apr;21(2):81-91. doi: 10.7224/1537-2073.2018-033.
Summary(link is external)
Read the full text of this paper (link is external)
Waubant E, Banwell B, Wassmer E, Sormani MP, Amato MP, Hintzen R, Krupp L, Rostásy K, Tenembaum S, Chitnis T; IPMSSG..
Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG.
Neurology. 2019 May 28;92(22):e2538-e2549. doi: 10.1212/WNL.0000000000007572. Epub 2019 May 1.
Summary(link is external)
Read the full text of this paper (link is external)
Hebert D, Geisthardt C, Hoffman H.
Insights and recommendations from parents receiving a diagnosis of pediatric multiple sclerosis for their child.
J Child Neurol. 2019 Apr 23:883073819842420. doi: 10.1177/0883073819842420. [Epub ahead of print]
Summary(link is external)
Florea A, Maurey H, Le Sauter M, Bellesme C, Sevin C, Deiva K.
Fatigue, depression, and quality of life in children with multiple sclerosis: a comparative study with other demyelinating diseases.
Dev Med Child Neurol. 2019 Apr 11. doi: 10.1111/dmcn.14242. [Epub ahead of print]
Summary(link is external)
Co-existing conditions
D'Amico E, Chisari CG, Arena S, Zanghì A, Toscano S, Lo Fermo S, Maimone D, Castaing M, Sciacca S, Zappia M, Patti F.
Cancer risk and multiple sclerosis: evidence from a large Italian cohort.
Front Neurol. 2019 Apr 10;10:337. doi: 10.3389/fneur.2019.00337. eCollection 2019.
Summary(link is external)
Read the full text of this paper (link is external)
Diagnosis
Calabrese M, Gasperini C, Tortorella C, Schiavi G, Frisullo G, Ragonese P, Fantozzi R, Prosperini L, Annovazzi P, Cordioli C, Di Filippo M, Ferraro D, Gajofatto A, Malucchi S, Lo Fermo S, De Luca G, Stromillo ML, Cocco E, Gallo A, Paolicelli D, Lanzillo R, Tomassini V, et al.
Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study.
Neurology. 2019 May 28;92(22):e2527-e2537. doi: 10.1212/WNL.0000000000007573. Epub 2019 May 1.
Summary(link is external)
Read the full text of this paper (link is external)
Schmierer K, Campion T, Sinclair A, van Hecke W, Matthews PM, Wattjes MP.
Towards a standard MRI protocol for multiple sclerosis across the UK.
Br J Radiol. 2019 May 14:20180926. doi: 10.1259/bjr.20180926. [Epub ahead of print]
Summary(link is external)
Hartung HP, Graf J, Aktas O, Mares J, Barnett MH.
Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 - continuity and change.
Curr Opin Neurol. 2019 Jun;32(3):327-337. doi: 10.1097/WCO.0000000000000699.
Summary(link is external)
Disease modifying drugs
D'Amico E, Zanghì A, Gastaldi M, Patti F, Zappia M, Franciotta D.
Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives.
Autoimmun Rev. 2019 May 3. pii: S1568-9972(19)30105-3. doi: 10.1016/j.autrev.2019.05.003. [Epub ahead of print] Review.
Summary(link is external)
Drulovic J, Ivanovic J, Mesaros S, Martinovic V, Kisic-Tepavcevic D, Dujmovic I, Pekmezovic T.
Long-term disability outcomes in relapsing-remitting multiple sclerosis: a 10-year follow-up study.
Neurol Sci. 2019 Apr 22. doi: 10.1007/s10072-019-03878-4. [Epub ahead of print]
Summary(link is external)
Phelps R, Winston JA, Wynn D, Habek M, Hartung HP, Havrdová EK, Markowitz GS, Margolin DH, Rodriguez CE, Baker DP, Coles AJ.
Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis.
Mult Scler. 2019 Apr 15:1352458519841829. doi: 10.1177/1352458519841829. [Epub ahead of print]
Summary(link is external)
Read the full text of this paper (link is external)
Schweitzer F, Laurent S, Fink GR, Barnett MH, Reddel S, Hartung HP, Warnke C.
Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis.
Curr Opin Neurol. 2019 Jun;32(3):305-312. doi: 10.1097/WCO.0000000000000701.
Summary(link is external)
Cree BAC, Mares J, Hartung HP.
Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm.
Curr Opin Neurol. 2019 Jun;32(3):365-377. doi: 10.1097/WCO.0000000000000700.
Summary(link is external)
Drugs in development
Waslo C, Bourdette D, Gray N, Wright K, Spain R.
Lipoic acid and other antioxidants as therapies for multiple sclerosis.
Curr Treat Options Neurol. 2019 May 6;21(6):26. doi: 10.1007/s11940-019-0566-1. Review.
Summary(link is external)
Ancau M, Berthele A, Hemmer B.
CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date.
Expert Opin Biol Ther. 2019 May 24:1-15. doi: 10.1080/14712598.2019.1611778. [Epub ahead of print]
Summary(link is external)
Bhatia R, Singh N.
Can we treat secondary progressive multiple sclerosis now?
Ann Indian Acad Neurol. 2019 Apr-Jun;22(2):131-136. doi: 10.4103/aian.AIAN_345_18. Review.
Summary(link is external)
Read the full text of this paper (link is external)
De Angelis F, Chataway J.
Novel multiple sclerosis drugs in the pipeline.
Clin Pharmacol Ther. 2019 May;105(5):1082-1090. doi: 10.1002/cpt.1412. No abstract available.
Summary(link is external)
Read the full text of this paper (link is external)
Epidemiology
Vaughn CB, Jakimovski D, Kavak KS, Ramanathan M, Benedict RHB, Zivadinov R, Weinstock-Guttman B.
Epidemiology and treatment of multiple sclerosis in elderly populations.
Nat Rev Neurol. 2019 Apr 18. doi: 10.1038/s41582-019-0183-3. [Epub ahead of print] Review.
Summary(link is external)
Other treatments
Salemi G, Vazzoler G, Ragonese P, Bianchi A, Cosentino G, Croce G, Gangitano M, Portera E, Realmuto S, Fierro B, Brighina F.
Application of tRNS to improve multiple sclerosis fatigue: a pilot, single-blind, sham-controlled study.
J Neural Transm (Vienna). 2019 Jun;126(6):795-799. doi: 10.1007/s00702-019-02006-y. Epub 2019 May 3.
Summary(link is external)
Gupta S, Fellows K, Weinstock-Guttman B, Hagemeier J, Zivadinov R, Ramanathan M.
Marijuana use by patients with multiple sclerosis.
Int J MS Care. 2019 Mar-Apr;21(2):57-62. doi: 10.7224/1537-2073.2017-112.
Summary(link is external)
Read the full text of this paper (link is external)
Rodriguez-Leal FA, Haase R, Akgün K, Eisele J, Proschmann U, Schultheiss T, Kern R, Ziemssen T.
Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting.
Ther Adv Chronic Dis. 2019 Apr 19;10:2040622319835136. doi: 10.1177/2040622319835136. eCollection 2019.
Summary(link is external)
Read the full text of this paper (link is external)
Lebrun C, Vukusic S; on behalf the French Group for Recommendations in Multiple Sclerosis France4MS the Société francophone de la sclérose en plaques SFSEP..
Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society.
Rev Neurol (Paris). 2019 Apr 26. pii: S0035-3787(19)30594-6. doi: 10.1016/j.neurol.2019.04.001. [Epub ahead of print]
Summary(link is external)
Karnoe A, Pedersen LM, Karlsen S, Boesen F, Skovgaard L, Kayser L.
How people with multiple sclerosis experience the influence of nutrition and lifestyle factors on the disease.
Disabil Rehabil. 2019 Apr 24:1-12. doi: 10.1080/09638288.2019.1602675. [Epub ahead of print]
Summary(link is external)
Restivo DA, Alfonsi E, Casabona A, Hamdy S, Tassorelli C, Panebianco M, Marchese-Ragona R, Quartarone A, Centonze D, Pavone A, Stampanoni Bassi M.
A pilot study on the efficacy of transcranial direct current stimulation applied to the pharyngeal motor cortex for dysphagia associated with brainstem involvement in multiple sclerosis.
Clin Neurophysiol. 2019 Jun;130(6):1017-1024. doi: 10.1016/j.clinph.2019.04.003. Epub 2019 Apr 11.
Summary(link is external)
Street T, Peace C, Padfield E, Singleton C.
Abdominal functional electrical stimulation for bowel management in multiple sclerosis.
Neurodegener Dis Manag. 2019 Apr;9(2):83-89. doi: 10.2217/nmt-2018-0043. Epub 2019 Apr 18.
Summary(link is external)
Renfrew LM, Paul L, McFadyen A, Rafferty D, Moseley O, Lord AC, Bowers R, Mattison P.
The clinical- and cost-effectiveness of functional electrical stimulation and ankle-foot orthoses for foot drop in Multiple Sclerosis: a multicentre randomized trial.
Clin Rehabil. 2019 Apr 11:269215519842254. doi: 10.1177/0269215519842254. [Epub ahead of print]
Summary(link is external)
Pregnancy
Coyle PK, Oh J, Magyari M, Oreja-Guevara C, Houtchens M.
Management strategies for female patients of reproductive potential with multiple sclerosis: An evidence-based review.
Mult Scler Relat Disord. 2019 Apr 5;32:54-63. doi: 10.1016/j.msard.2019.04.003. [Epub ahead of print] Review.
Summary(link is external)
Read the full text of this paper (link is external)
Cuello JP, Martínez Ginés ML, Kuhle J, García Domínguez JM, Lozano Ros A, Romero Delgado F, Higueras Y, Meldaña Rivera A, Goicochea Briceño H, García-Tizon Larroca S, de-León Ruiz J, Michalak Z, Barro C, Álvarez Lafuente R, Medina Heras S, Fernández Velasco JI, Tejeda-Velarde A, Domínguez-Mozo MI, Muriel A, de Andrés C, Villar LM.
Neurofilament light chain levels in pregnant multiple sclerosis patients: a prospective cohort study.
Eur J Neurol. 2019 Apr 12. doi: 10.1111/ene.13965. [Epub ahead of print]
Summary(link is external)
Provision of care
Yeroushalmi S, Maloni H, Costello K, Wallin MT.
Telemedicine and multiple sclerosis: a comprehensive literature review.
J Telemed Telecare. 2019 May 1:1357633X19840097. doi: 10.1177/1357633X19840097. [Epub ahead of print]
Summary(link is external)
Psychological aspects
Bassi M, Cilia S, Falautano M, Grobberio M, Niccolai C, Pattini M, Pietrolongo E, Quartuccio ME, Viterbo RG, Allegri B, Amato MP, Benin M, De Luca G, Gasperini C, Minacapelli E, Patti F, Trojano M, Delle Fave A.
Illness perceptions and psychological adjustment among persons with multiple sclerosis: the mediating role of coping strategies and social support.
Disabil Rehabil. 2019 May 6:1-13. doi: 10.1080/09638288.2019.1610511. [Epub ahead of print]
Summary(link is external)
Santos M, Sousa C, Pereira M, Pereira MG.
Quality of life in patients with multiple sclerosis: A study with patients and caregivers.
Disabil Health J. 2019 Mar 28. pii: S1936-6574(19)30052-4. doi: 10.1016/j.dhjo.2019.03.007. [Epub ahead of print]
Summary(link is external)
Koutsogeorgou E, Chiesi AM, Leonardi M.
Social capital components and social support of persons with multiple sclerosis: a systematic review of the literature from 2000 to 2018.
Disabil Rehabil. 2019 Apr 18:1-13. doi: 10.1080/09638288.2019.1597182. [Epub ahead of print]
Summary(link is external)
Rehabilitation
Dana A, Rafiee S, Gholami A.
Motor reaction time and accuracy in patients with multiple sclerosis: effects of an active computerized training program.
Neurol Sci. 2019 May 4. doi: 10.1007/s10072-019-03892-6. [Epub ahead of print]
Summary(link is external)
Bollaert RE, Motl RW.
Self-efficacy and physical and cognitive function in older adults with multiple sclerosis.
Int J MS Care. 2019 Mar-Apr;21(2):63-69. doi: 10.7224/1537-2073.2018-001.
Summary(link is external)
Read the full text of this paper (link is external)
Mañago MM, Glick S, Hebert JR, Coote S, Schenkman M.
Strength training to improve gait in people with multiple sclerosis: a critical review of exercise parameters and intervention approaches.
Int J MS Care. 2019 Mar-Apr;21(2):47-56. doi: 10.7224/1537-2073.2017-079.
Summary(link is external)
Read the full text of this paper (link is external)
Groppo E, Signori A, Sormani MP, Grosso C, Mantia L, Cattaneo D, Rovaris M.
Predictors of hospital-based multidisciplinary rehabilitation effects in persons with multiple sclerosis: a large-scale, single-centre study.
Mult Scler J Exp Transl Clin. 2019 Apr 16;5(2):2055217319843673. doi: 10.1177/2055217319843673. eCollection 2019 Apr-Jun.
Summary(link is external)
Read the full text of this paper (link is external)
Smith M, Neibling B, Williams G, Birks M, Barker R.
A qualitative study of active participation in sport and exercise for individuals with multiple sclerosis.
Physiother Res Int. 2019 Apr 22:e1776. doi: 10.1002/pri.1776. [Epub ahead of print]
Summary(link is external)
Kannan M, Hildebrand A, Hugos CL, Chahine R, Cutter G, Cameron MH.
Evaluation of a web-based fall prevention program among people with multiple sclerosis.
Mult Scler Relat Disord. 2019 Apr 13;31:151-156. doi: 10.1016/j.msard.2019.04.015. [Epub ahead of print]
Summary(link is external)
Krause A, Lee K, Freyler K, Bührer T, Gollhofer A, Ritzmann R.
Whole-body vibration impedes the deterioration of postural control in patients with multiple sclerosis.
Mult Scler Relat Disord. 2019 Apr 3;31:134-140. doi: 10.1016/j.msard.2019.03.026. [Epub ahead of print]
Summary(link is external)
Relapses
Koch-Henriksen N, Thygesen LC, Sørensen PS, Magyari M.
Worsening of disability caused by relapses in multiple sclerosis: A different approach.
Mult Scler Relat Disord. 2019 Apr 15;32:1-8. doi: 10.1016/j.msard.2019.04.017. [Epub ahead of print]
Summary(link is external)
Stem cells
Gale RP, Gómez-Cruz GB, Olivares-Gazca JC, León-Peña AA, Gómez-Almaguer D, Gómez-De-León A, González-López EE, Ruiz-Argüelles A, Soto-Vega E, Muñoz-Pérez MJ, Ruiz-Delgado GJ, Ruiz-Argüelles GJ.
Determine safety of outpatient chemotherapy and autotransplants using refrigerated, non-frozen grafts in persons with multiple sclerosis.
Clin Transplant. 2019 Apr 20:e13567. doi: 10.1111/ctr.13567. [Epub ahead of print]
Summary(link is external)
Mehra V, Rhone E, Widya S, Zuckerman M, Potter V, Raj K, Kulasekararaj A, McLornan D, de Lavallade H, Benson-Quarm N, Lim C, Ware S, Sudhanva M, Malik O, Nicholas R, Muraro PA, Marsh J, Mufti GJ, Silber E, Pagliuca A, Kazmi MA.
Epstein-Barr Virus and monoclonal gammopathy of clinical significance in autologous stem cell transplantation for multiple sclerosis.
Clin Infect Dis. 2019 Jan 15. pii: ciz047. doi: 10.1093/cid/ciz047. [Epub ahead of print]
Summary(link is external)
Symptoms and symptom management
Linnhoff S, Fiene M, Heinze HJ, Zaehle T.
Cognitive fatigue in multiple sclerosis: an objective approach to diagnosis and treatment by transcranial electrical stimulation.
Brain Sci. 2019 May 2;9(5). pii: E100. doi: 10.3390/brainsci9050100. Review.
Summary(link is external)
Read the full text of this paper (link is external)
Stimmel M, Shagalow S, Seng EK, Portnoy JG, Archetti R, Mendelowitz E, Sloan J, Botvinick J, Glukhovsky L, Foley FW.
Short report: adherence to neuropsychological recommendations in patients with multiple sclerosis.
Int J MS Care. 2019 Mar-Apr;21(2):70-75. doi: 10.7224/1537-2073.2017-089.
Summary(link is external)
Read the full text of this paper (link is external)
Hu M, Muhlert N, Robertson N, Winter M.
Perceived fatigue and cognitive performance change in multiple sclerosis: Uncovering predictors beyond baseline fatigue.
Mult Scler Relat Disord. 2019 Apr 16;32:46-53. doi: 10.1016/j.msard.2019.04.011. [Epub ahead of print]
Summary(link is external)
Owji M, Ashraf-Ganjouei A, Sahraian MA, Bidadian M, Ghadiri F, Naser Moghadasi A.
The relationship between cognitive function and body mass index in multiple sclerosis patients.
Mult Scler Relat Disord. 2019 Apr 21;32:37-40. doi: 10.1016/j.msard.2019.04.024. [Epub ahead of print]
Summary(link is external)
Mordillo-Mateos L, Soto-Leon V, Torres-Pareja M, Peinado-Palomino D, Mendoza-Laiz N, Alonso-Bonilla C, Dileone M, Rotondi M, Aguilar J, Oliviero A.
Fatigue in multiple sclerosis: general and perceived fatigue does not depend on corticospinal tract dysfunction.
Front Neurol. 2019 Apr 9;10:339. doi: 10.3389/fneur.2019.00339. eCollection 2019.
Summary(link is external)
Read the full text of this paper (link is external)
Angela S, Tullia SD, Giorgia F, Valter S, Teresa P.
Occupational therapy in fatigue management in multiple sclerosis: an umbrella review.
Mult Scler Int. 2019 Mar 21;2019:2027947. doi: 10.1155/2019/2027947. eCollection 2019. Review.
Summary(link is external)
Read the full text of this paper (link is external)
Branco M, Ruano L, Portaccio E, Goretti B, Niccolai C, Patti F, Chisari C, Gallo P, Grossi P, Ghezzi A, Roscio M, Mattioli F, Bellomi F, Simone M, Viterbo RG, Amato MP.
Aging with multiple sclerosis: prevalence and profile of cognitive impairment.
Neurol Sci. 2019 Apr 23. doi: 10.1007/s10072-019-03875-7. [Epub ahead of print]
Summary(link is external)
Gava G, Visconti M, Salvi F, Bartolomei I, Seracchioli R, Meriggiola MC.
Prevalence and psychopathological determinants of sexual dysfunction and related distress in women with and without multiple sclerosis.
J Sex Med. 2019 Apr 19. pii: S1743-6095(19)30467-9. doi: 10.1016/j.jsxm.2019.03.011. [Epub ahead of print]
Summary(link is external)
Gullo HL, Fleming J, Bennett S, Shum DHK.
Cognitive and physical fatigue are associated with distinct problems in daily functioning, role fulfilment, and quality of life in multiple sclerosis.
Mult Scler Relat Disord. 2019 Apr 1;31:118-123. doi: 10.1016/j.msard.2019.03.024. [Epub ahead of print]
Summary(link is external)
Staudt MD, Joswig H, Pickett GE, MacDougall KW, Parrent AG.
Percutaneous glycerol rhizotomy for trigeminal neuralgia in patients with multiple sclerosis: a long-term retrospective cohort study.
J Neurosurg. 2019 Apr 12:1-9. doi: 10.3171/2019.1.JNS183093. [Epub ahead of print]
Summary(link is external)


Ozanimod (Zeposia) approved for relapsing remitting MS in Scotland
8 Feb 2021 - 00:00
The MS Trust is delighted that ozanimod (Zeposia) has been approved in Scotland for people with active relapsing remitting multiple sclerosis.


Exercise is good for your brain
3 Feb 2021 - 00:00
There is more to exercise than physical fitness. This review looks at recent research which shows how exercise has a direct beneficial effect on brain repair processes.


Covid-19 vaccines and MS: Part two
29 Jan 2021 - 00:00
Following our last interview on the subject of the Covid-19 vaccine and people with MS, we received a lot of follow up questions. To answer some of these, we spoke once again to Professor Alasdair Coles, Consultant Neurologist at Addenbrooke’s hospital.

Sign up to our emails
Get the latest news and research sent straight to your inbox. Find out first about the latest developments in MS treatments, plus updates on the work of the MS Trust.